UroAlert - GU Oncology Daily

June 19, 2026

Videos

Peer-to-Peer Clinical Conversations

PROTEUS Trial Results for Apalutamide plus ADT Before and After Radical Prostatectomy - Fred Saad

Fred Saad

Fred Saad discusses PROTEUS trial results.

View

Cost-Effectiveness of BCG plus Immune Checkpoint Inhibitors in High-Risk NMIBC - Daniel Joyce

Daniel Joyce

Daniel Joyce discusses cost-effectiveness of adding immune checkpoint inhibitors to BCG in high-risk non-muscle invasive bladder cancer, drawing on Markov modeling applied to trials including CREST, POTOMAC, and ALBAN.

View

Beyond the Abstracts

Real-World Effectiveness of Avelumab, Pembrolizumab, and Enfortumab Vedotin in Patients with Advanced Urothelial Carcinoma with Squamous Differentiation (ARON-2EV) - Beyond the Abstract

Surgical Management of Nonmetastatic Renal Cell Carcinoma with Inferior Vena Cava Thrombus: A Systematic Review and Network Meta-analysis - Beyond the Abstract

Conference Coverage

ASCO 2026: Selective Bladder-Sparing Trial with Sasanlimab as Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized MIBC Patients: SASAN-SPARING Trial

ASCO 2026: Analysis of Genomic and Clinical Predictors of Overall Survival and PSA Response: Results from the PRECISION Registry

ASCO 2026: A Prospective, Multi-Center, Phase 1b/II Trial of First-Line Cadonilimab + Axitinib in Advanced Non-Clear Cell RCC

AUA 2026: Differences in Patient-Reported and Objective Functional Recovery Trajectories Following Radical Cystectomy: Findings from the UW Prospective Bounceback Cohort Study

AUA 2026: Adding Upfront, Perioperative Durvalumab vs Adopting Risk-Adapted Adjuvant Nivolumab? Cost-Effectiveness Analysis of Competing Treatment Strategies for Cisplatin-Eligible MIBC in the Era of Immune Checkpoint Inhibitors

Articles

Editor Selected Abstracts and Commentaries

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

UroAlert - GU Oncology Daily

Bladder Cancer

Renal Cancer

Prostate Cancer

Upper Tract Tumors

Login